Follow-up data based on CCA tissue microarrays confirmed RBM10 downregulation in tumors correlating with reduced overall survival (P = 0.0487) and recurrence-free survival (P = 0.0207) (Fig. 2. This evidence concerns the gene RBM10 and cholangiocarcinoma.